Eric P Rahrmann
Overview
Explore the profile of Eric P Rahrmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
868
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robbins G, Vue Y, Rahrmann E, Moriarity B
Med Res Arch
. 2025 Feb;
12(11).
PMID: 39916749
Osteosarcoma (OSA) is a highly malignant bone tumor for which more than 50% of patients have or will develop metastatic disease, resulting in an abysmal 5-year survival rate of <29%....
2.
Patritti-Cram J, Rahrmann E, Rizvi T, Scheffer K, Phoenix T, Largaespada D, et al.
iScience
. 2024 Aug;
27(7):110294.
PMID: 39100928
The blood-nerve-barrier (BNB) that regulates peripheral nerve homeostasis is formed by endoneurial capillaries and perineurial cells surrounding the Schwann cell (SC)-rich endoneurium. Barrier dysfunction is common in human tumorigenesis, including...
3.
Shorthouse D, Zhuang L, Rahrmann E, Kosmidou C, Wickham Rahrmann K, Hall M, et al.
Life Sci Alliance
. 2023 Sep;
6(12).
PMID: 37748809
Voltage-sensitive potassium channels play an important role in controlling membrane potential and ionic homeostasis in the gut and have been implicated in gastrointestinal (GI) cancers. Through large-scale analysis of 897...
4.
Jassim A, Rahrmann E, Simons B, Gilbertson R
Nat Rev Cancer
. 2023 Jul;
23(10):710-724.
PMID: 37488363
Cancer has been a leading cause of death for decades. This dismal statistic has increased efforts to prevent the disease or to detect it early, when treatment is less invasive,...
5.
Rahrmann E, Shorthouse D, Jassim A, Hu L, Ortiz M, Mahler-Araujo B, et al.
Nat Genet
. 2022 Sep;
54(12):1827-1838.
PMID: 36175792
We identify the sodium leak channel non-selective protein (NALCN) as a key regulator of cancer metastasis and nonmalignant cell dissemination. Among 10,022 human cancers, NALCN loss-of-function mutations were enriched in...
6.
Watson A, Keller B, Williams K, Damle N, Finnerty S, Anderson L, et al.
Oncotarget
. 2020 Oct;
11(39):3618-3620.
PMID: 33062197
[This corrects the article DOI: 10.18632/oncotarget.1609.].
7.
Smeester B, Draper G, Slipek N, Larsson A, Stratton N, Pomeroy E, et al.
Mol Cancer Ther
. 2020 Oct;
19(12):2528-2541.
PMID: 32999043
We previously identified as an oncogenic driver of a subset of osteosarcomas using the () transposon system. Here, we followed up by investigating the genetic role of in osteosarcoma initiation...
8.
Smeester B, Slipek N, Pomeroy E, Laoharawee K, Osum S, Larsson A, et al.
Bone
. 2020 Apr;
136:115353.
PMID: 32251854
Osteosarcoma (OSA) is a heterogeneous and aggressive solid tumor of the bone. We recently identified the colony stimulating factor 1 receptor (Csf1r) gene as a novel driver of osteosarcomagenesis in...
9.
Smeester B, Slipek N, Pomeroy E, Bomberger H, Shamsan G, Peterson J, et al.
Oncogene
. 2019 Oct;
39(5):1049-1062.
PMID: 31582836
Semaphorins, specifically type IV, are important regulators of axonal guidance and have been increasingly implicated in poor prognoses in a number of different solid cancers. In conjunction with their cognate...
10.
Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors
Beckmann P, Larson J, Larsson A, Ostergaard J, Wagner S, Rahrmann E, et al.
Cancer Res
. 2019 Jan;
79(5):905-917.
PMID: 30674530
Medulloblastoma and central nervous system primitive neuroectodermal tumors (CNS-PNET) are aggressive, poorly differentiated brain tumors with limited effective therapies. Using () transposon mutagenesis, we identified novel genetic drivers of medulloblastoma...